Namodenoson
Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is developed by Can-Fite for non-alcoholic fatty liver disease,[1] liver cancer,[2] and pancreatic cancer.[3]
References
- ^ Safadi, Rifaat; Braun, Marius; Francis, Adi; Milgrom, Yael; Massarwa, Muhammad; Hakimian, David; Hazou, Wadi; Issachar, Assaf; Harpaz, Zivit; Farbstein, Motti; Itzhak, Inbal; Lev-Cohain, Naama; Bareket-Samish, Avital; Silverman, Michael H.; Fishman, Pnina (December 2021). "Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis". Alimentary Pharmacology & Therapeutics. 54 (11–12): 1405–1415. doi:10.1111/apt.16664. ISSN 1365-2036.
- ^ Stemmer, Salomon M.; Manojlovic, Nebojsa S.; Marinca, Mihai Vasile; Petrov, Petar; Cherciu, Nelly; Ganea, Doina; Ciuleanu, Tudor Eliade; Pusca, Ioana Adriana; Beg, Muhammad Shaalan; Purcell, William T.; Croitoru, Adina-Emilia; Ilieva, Rumyana Nedyalkova; Natošević, Sladjana; Nita, Amedeia Lavinir; Kalev, Dimitar Nikolaev; Harpaz, Zivit; Farbstein, Motti; Silverman, Michael H.; Bristol, David; Itzhak, Inbal; Fishman, Pnina (7 January 2021). "Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial". Cancers. 13 (2): 187. doi:10.3390/cancers13020187. ISSN 2072-6694.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Fishman, Pnina; Bareket-Samish, Avital; Itzhak, Inbal (1 June 2023). "Effects of namodenoson on pancreatic carcinoma: Preclinical evidence". Journal of Clinical Oncology. 41 (16_suppl): e15134–e15134. doi:10.1200/JCO.2023.41.16_suppl.e15134.